Kasvua hakemassa! Pharmatest participated in KasvuOpen Carneval in Jyväskylä on the 31st of October. (Jukka Rissanen, Petri Laine) #kasvuopen #pharmatest
Pharmatest Services
Biotechnology Research
Pharmatest is a CRO that offers preclinical efficacy services in therapeutic areas of oncology and skeletal diseases.
About us
Pharmatest Services (Pharmatest) is a preclinical contract research organization offering translational research services for diseases with unmet clinical needs. We offer full-service research solutions for early drug development. Our focus is on preclinical efficacy models in the fields of cancer and skeletal diseases ranging from in vitro cell culture assays to in vivo models. In addition, we provide model and assay development services for our customers. Pharmatest can help you establish the proof-of-efficacy of your cancer drug candidates with clinically predictive cell culture assays, organotypic 3D models, orthotopic animal models, and disseminated cancer models. Our models of skeletal diseases include clinically predictive bone cell culture assays and animal models of osteoporosis and osteoarthritis that can also be used for bone safety testing. Our services have been developed with just one goal in mind – to make your nonclinical drug development faster and more predictive. Our mission is to reduce the amount of drug candidates failing in clinical trials. Outsource your preclinical efficacy testing to Pharmatest and increase significantly the speed of your drug development with reduced costs.
- Sivusto
-
http://www.pharmatest.com
External link for Pharmatest Services
- Toimiala
- Biotechnology Research
- Yrityksen koko
- 11–50 työntekijää
- Päätoimipaikka
- Turku
- Tyyppi
- Privately Held
- Perustettu
- 1998
- Erityisosaaminen
Sijainnit
-
Ensisijainen
Get directions
Itäinen Pitkäkatu 4 A
Turku, 20520, FI
-
Get directions
25B Stow Road
Boxborough, MA 01719, US
Työntekijät Pharmatest Services
Päivitykset
-
October is Breast Cancer Awareness Month. As a contract research organization, we are proud to play a role in the preclinical studies that pave the way for innovative treatments and breakthroughs in breast cancer research. Let’s unite in our efforts to educate, advocate, and innovate in the fight against breast cancer. Every action counts! #BreastCancerAwarenessMonth #CRO #PreclinicalResearch #CancerResearch
-
-
Pharmatest has participated in Rare Bone Disease Symposium and ASBMR 2024 for the past few days. Lots of great science and interesting discussions! #ASBMR2024 #pharmatest #CRO #rarebonediseases
-
-
Today, the 27th of September, is European Myeloma Day. Pharmatest is honoured to participate in the research to battle multiple myeloma with NK ENGAGE Consortium. Thank you for the insightful meeting in Oslo hosted by Kalle Malmberg's team! #multiplemyeloma #eurostars #pharmatest
During a recent NK Engage Consortium meeting in Oslo, with Kalle Malmberg's team as fantastic hosts, representatives from Oncopeptides AB (publ) had the opportunity to engage in lively discussions and exchange ideas in an atmosphere of knowledge sharing and collaboration. In addition to Oncopeptides and the Malmberg Lab, representing partner Oslo University Hospital, representatives from Pharmatest Services and KTH Royal Institute of Technology also participated. The focus was on planning the upcoming studies for the third and final year of the project, which is co-financed by Eurostars 3, the EU's research and innovation program Horizon Europe, and Vinnova. We look forward to continuing this exciting work together!
-
-
Pharmatest was excited to join the NK-ENGAGE consortium for a productive face-to-face meeting in Oslo! This ambitious Eurostars and Business Finland -funded R&D project is focused on creating an innovative synthetic small polypeptide for treating multiple myeloma (MM), as well as developing advanced preclinical models in the presence of human immune cells. We are proud to collaborate with a strong alliance of distinguished institutions and biotech firms, including Oncopeptides AB (publ) (Sweden), KTH Royal Institute of Technology in Stockholm, and Oslo University Hospital. The discussions we had were truly inspiring and highlighted the potential for groundbreaking advancements in MM therapy. Learn more about this exciting initiative here: https://lnkd.in/dwTtfQEi https://lnkd.in/dStH3MZR Eurostars is part of the European Partnership on Innovative SMEs. The partnership is co-funded by the European Union through Horizon Europe. #eurostars #multiplemyeloma #researchanddevelopment #preclinicalresearch
-
-
Pharmatest is among the TOP 60 companies chosen by Kasvu Open! We are thrilled to be part of this great group of companies and looking forward to the next steps of the journey. 💚 #kasvuopen #pharmatest
💚 Kasvuyritysten TOP 60 on valittu! 💚 Poppoo on valikoitunut yli 200 Kasvupolku®-sparraukseen osallistuneen yrityksen joukosta kasvusuunnitelmien ja -potentiaalin pohjalta. 👉 Joukko aikoo lähes kolminkertaistaa liikevaihtonsa seuraavan kolmen vuoden aikana. Kovien kasvutavoitteiden ansiosta yrityksillä on myös työllistämisvoimaa: uusia tekijöitä tarvitaan yhteensä yli 900. TOP 60 jatkaa liiketoiminnan kehittämistä asiantuntijoiden kanssa ja kisaa Vuoden kasvuyritys -tittelistä. Tittelin saaja valitaan ja julkistetaan yritystapahtuma Kasvu Open Karnevaalissa 31.10.2024. Tule tapaamaan yritykset Jyväskylään ja verkostoitumaan satojen uusien tyyppien kanssa - osallistuminen ei maksa mitään! #kasvu #kasvuopen #yritykset
-
-
We are hiring! Pharmatest is looking for a motivated and skilled Research Assistant with experience on in vivo work and/or histology. More information about the position and how to apply can be found on our websites: https://lnkd.in/dqQPd-2M #hiring #researchassistant #pharmatest
-
-
Pharmatest will participate in ASBMR Annual Meeting 2024 and Rare Bone Disease Symposium on Exploring and Expanding Treatments and Analytical Tools in Rare Bone Diseases, September 26-30 in Toronto! We will present a poster "Effects of Anabolic Treatments with Teriparatide and Romosozumab on Bone in /G610C Mouse Model of Adult Osteogenesis Imperfecta" with presentation numbers Sat-183 (ASBMR) and PM-116 (Rare Bone Diseases). Let us know if you would like to schedule a meeting with our CEO Jukka Rissanen to discuss how Pharmatest could help you with your research. #ASBMR2024 #rarediseases #bonediseases #CRO #preclinicalresearch #pharmatest
-
-
Pharmatest attended the 18th Health BIO in Turku! An interesting event with good conversations and insights to the bio and pharma industry. #healthbio #biotech #pharma #pharmatest
-
-
Pharmatest is taking part in Kilometrikisa, which is a playful cycling competition between work communities, associations, clubs, hobby groups, friends or any kind of teams. Kilometrikisa takes place between 1.5.-30.9.2024. Our team name is Pharmatest Riders. 😎 🚲 #kilometrikisa #pharmatest #cycling
-